Rabpharma is dedicated to the R&D of first-in-class new drugs in the field of bone and joint diseases. 

 Since establishment, we have built a comprehensive set of technology platforms, including PDC conjugation and high-throughput screening. 
        Rabpharma's  two lead products:  RAB-001 (Indication：Osteonecrosis; U.S. Phase I & China bridging completed, Phase II data readout in 2026 ) and RAB-001d (Indication：Knee OA; Phase Ib ongoing, completion expected May 2027).